Peer-influenced content. Sources you trust. No registration required. This is HCN.

Ibrutinib May Improve Pulmonary Outcomes in Certain COVID-19 Cases

Although the findings reported in Blood should be considered as hypothesis-generating and preliminary in nature, a small clinical trial suggested ibrutinib may protect against lung injury and improve pulmonary function in hypoxic patients with COVID-19.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form